Last reviewed · How we verify

NCT04917497

Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock

Completed Last updated 8 June 2021
What this trial tests

trial testing Levosimendan in Cardiogenic Shock in 43 participants. Completed in 30 April 2014.

Timeline
30 June 2011
Primary endpoint
30 April 2014
30 April 2014

Quick facts

Lead sponsorUniversity of Zurich
StatusCompleted
Study typeOBSERVATIONAL
Enrollment43
Start date30 June 2011
Primary completion30 April 2014
Estimated completion30 April 2014

Drugs / interventions tested

Conditions studied

Sponsor

University of Zurich

Who can join

18 and older, any sex, with Cardiogenic Shock or Cardiorenal Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine whether Levosimendan infusion in patients with cardiogenic shock and cardiorenal syndrome refractory to standard inotropic therapy, improves hemodynamics and renal function, whilst being safe.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Levosimendan

Trials testing the same drug.

Other recruiting trials for Cardiogenic Shock

Currently open trials in the same condition.

Other University of Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04917497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing